Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Issues a Voluntary Global Recall of Multiple Lots of Ketorolac Tromethamine Injection Due to Potential Particulate in Glass Vials

02/11/2015 10:09 AM EST

Hospira, Inc., (NYSE: HSP) has announced a voluntary recall of ketorolac tromethamine injection, USP in the United States and Singapore due to potential particulate. The presence of particulate has been confirmed through a customer report of visible, floating particulate identified in glass fliptop vials.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420